QuidelOrtho Faces Price Target Cut Amid Mixed Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Source: Fool
QuidelOrtho Corp's shares fell 17.41% as it crossed below the 5-day SMA, reflecting investor concerns following UBS's price target reduction.
UBS has lowered its price target for QuidelOrtho from $35 to $30 while maintaining a ‘Neutral’ rating, reflecting a cautious market outlook that may dampen investor confidence in the stock. The company anticipates revenue between $2.7 billion and $2.9 billion for fiscal 2026, aligning with Wall Street's estimate of $2.77 billion, but adjusted earnings per share are projected at $2.00 to $2.42, falling short of the estimated $2.51, indicating pressure on profitability. Additionally, the expected free cash flow of $120 million to $160 million in fiscal 2026 is significantly below the estimated $441 million, suggesting challenges in cost management and revenue growth that could impact future investment and expansion plans.
The mixed guidance and lowered price target have raised concerns among investors, leading to a significant drop in QuidelOrtho's stock price. The company's ability to manage costs and achieve revenue growth will be critical in restoring investor confidence and supporting its long-term growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QDEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QDEL
Wall Street analysts forecast QDEL stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 13.070
Low
35.00
Averages
35.00
High
35.00
Current: 13.070
Low
35.00
Averages
35.00
High
35.00
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: Hemolytic disease of the fetus and newborn (HDFN) is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advancements in screening and treatment, gaps in awareness and management persist.
- Podcast Content: Episode 58 of QuidelOrtho's Science Bytes podcast, hosted by Global Product Manager Michelle Mullens, features Bethany Weathersby, Founder of the Allo Hope Foundation, discussing the impact of red blood cell antibodies on pregnancy and the importance of clinical management.
- Importance of Laboratory Testing: The podcast emphasizes the critical role of laboratory testing in prenatal care decisions, highlighting that timely results can significantly improve outcomes for mothers and babies, particularly in well-resourced healthcare settings.
- Global Awareness Initiatives: The Allo Hope Foundation is dedicated to raising global awareness of HDFN, providing patient counseling, facilitating specialty referrals, and conducting disease research to ensure that survival from HDFN becomes a global expectation.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: HDFN is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advances in screening and treatment, inconsistencies in awareness and management persist.
- Impact of Awareness Gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delays in understanding and care, which negatively affects maternal and fetal health, highlighting the need for increased awareness.
- Importance of Laboratory Testing: Antibody screening and titers directly guide pregnancy management and risk assessment, with timely testing results significantly improving health outcomes for mothers and babies.
- Patient Perspective: By connecting diagnostic workflows to real-world outcomes, the discussion emphasizes opportunities to enhance care, particularly in well-resourced healthcare settings where timely access to expertise is crucial.
See More
QuidelOrtho Corporation to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: QuidelOrtho's management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 12:20 PM ET, aiming to attract investor interest in its innovative in vitro diagnostic products.
- Fireside Chat Event: On June 3, 2026, at the Jefferies Global Healthcare Conference, QuidelOrtho's management will participate in a fireside chat at 8:10 AM ET, further showcasing the company's market strategy and future development direction.
- Live Webcast Access: Interested investors can access the live webcast and replay of the conferences through the
See More
QuidelOrtho Corporation Q1 2026 Earnings Call Insights
- Revenue Decline: QuidelOrtho reported total revenue of $620 million in Q1, reflecting a significant decline due to a notably softer respiratory season, with influenza-like illness visits down approximately 30%, adversely impacting overall performance.
- China Market Slowdown: Sales in China slowed in March as distributors exercised caution ahead of anticipated national IVD pricing guidelines, with expected revenue declines of roughly $75 million, highlighting market uncertainties.
- Acquisition of LEX Diagnostics: The company completed the acquisition of LEX Diagnostics in April, adding a highly differentiated ultra-fast molecular platform, with measurable revenue expected to begin in early 2027, thereby strengthening its competitive position in point-of-care testing.
- Cash Flow Outlook: Despite a negative operating cash flow of $33 million in Q1, the company expects free cash flow for the full year to be in the range of $100 million to $120 million, indicating ongoing focus on cash flow generation and improvement plans.
See More
Quidel Scheduled to Announce Q1 Earnings on May 5th
- Earnings Announcement: Quidel (QDEL) is set to release its Q1 earnings on May 5th after market close, with a consensus EPS estimate of $0.42, reflecting a significant year-over-year decline of 43.2%, indicating potential profitability challenges ahead.
- Revenue Decline: The expected revenue for Q1 is $659.17 million, down 4.9% year-over-year, suggesting weakening market demand and increased competition may adversely affect the company's performance.
- Strong Historical Performance: Over the past two years, Quidel has consistently beaten both EPS and revenue estimates 100% of the time, demonstrating reliability in financial forecasting, although recent downward revisions raise concerns about future performance.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with four downward adjustments, and similarly, revenue estimates saw no upward revisions but three downward adjustments, indicating a decline in market confidence regarding the company's outlook.
See More
QuidelOrtho Releases Podcast on Syphilis Trends
- Syphilis Trend Analysis: QuidelOrtho's latest podcast discusses syphilis trends in the U.S., revealing that while primary and secondary syphilis cases have declined, congenital syphilis cases reached nearly 4,000 in 2024, highlighting a significant public health challenge.
- Screening Gaps: The podcast emphasizes that congenital syphilis is entirely preventable with timely diagnosis and treatment during pregnancy; however, current missed screening opportunities necessitate improvements in healthcare workflows to address this critical gap.
- CDC Data Insights: Andrea Ott-Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, interprets CDC data, indicating that despite a second consecutive year of decline in primary and secondary syphilis cases, the rising trend of congenital syphilis is alarming and requires urgent action.
- Actionable Recommendations: The podcast outlines actionable steps that health systems can take to enhance screening and treatment processes, thereby reducing the incidence of congenital syphilis and ensuring the health of mothers and newborns.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: Hemolytic disease of the fetus and newborn (HDFN) is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advancements in screening and treatment, gaps in awareness and management persist.
- Podcast Content: Episode 58 of QuidelOrtho's Science Bytes podcast, hosted by Global Product Manager Michelle Mullens, features Bethany Weathersby, Founder of the Allo Hope Foundation, discussing the impact of red blood cell antibodies on pregnancy and the importance of clinical management.
- Importance of Laboratory Testing: The podcast emphasizes the critical role of laboratory testing in prenatal care decisions, highlighting that timely results can significantly improve outcomes for mothers and babies, particularly in well-resourced healthcare settings.
- Global Awareness Initiatives: The Allo Hope Foundation is dedicated to raising global awareness of HDFN, providing patient counseling, facilitating specialty referrals, and conducting disease research to ensure that survival from HDFN becomes a global expectation.
See More
QuidelOrtho Releases Podcast Episode on HDFN Awareness and Care
- Overview of HDFN: HDFN is a serious condition driven by maternal alloimmunization that can lead to fetal anemia and other complications; despite advances in screening and treatment, inconsistencies in awareness and management persist.
- Impact of Awareness Gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delays in understanding and care, which negatively affects maternal and fetal health, highlighting the need for increased awareness.
- Importance of Laboratory Testing: Antibody screening and titers directly guide pregnancy management and risk assessment, with timely testing results significantly improving health outcomes for mothers and babies.
- Patient Perspective: By connecting diagnostic workflows to real-world outcomes, the discussion emphasizes opportunities to enhance care, particularly in well-resourced healthcare settings where timely access to expertise is crucial.
See More
QuidelOrtho Corporation to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: QuidelOrtho's management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 12:20 PM ET, aiming to attract investor interest in its innovative in vitro diagnostic products.
- Fireside Chat Event: On June 3, 2026, at the Jefferies Global Healthcare Conference, QuidelOrtho's management will participate in a fireside chat at 8:10 AM ET, further showcasing the company's market strategy and future development direction.
- Live Webcast Access: Interested investors can access the live webcast and replay of the conferences through the
See More
QuidelOrtho Corporation Q1 2026 Earnings Call Insights
- Revenue Decline: QuidelOrtho reported total revenue of $620 million in Q1, reflecting a significant decline due to a notably softer respiratory season, with influenza-like illness visits down approximately 30%, adversely impacting overall performance.
- China Market Slowdown: Sales in China slowed in March as distributors exercised caution ahead of anticipated national IVD pricing guidelines, with expected revenue declines of roughly $75 million, highlighting market uncertainties.
- Acquisition of LEX Diagnostics: The company completed the acquisition of LEX Diagnostics in April, adding a highly differentiated ultra-fast molecular platform, with measurable revenue expected to begin in early 2027, thereby strengthening its competitive position in point-of-care testing.
- Cash Flow Outlook: Despite a negative operating cash flow of $33 million in Q1, the company expects free cash flow for the full year to be in the range of $100 million to $120 million, indicating ongoing focus on cash flow generation and improvement plans.
See More
Quidel Scheduled to Announce Q1 Earnings on May 5th
- Earnings Announcement: Quidel (QDEL) is set to release its Q1 earnings on May 5th after market close, with a consensus EPS estimate of $0.42, reflecting a significant year-over-year decline of 43.2%, indicating potential profitability challenges ahead.
- Revenue Decline: The expected revenue for Q1 is $659.17 million, down 4.9% year-over-year, suggesting weakening market demand and increased competition may adversely affect the company's performance.
- Strong Historical Performance: Over the past two years, Quidel has consistently beaten both EPS and revenue estimates 100% of the time, demonstrating reliability in financial forecasting, although recent downward revisions raise concerns about future performance.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with four downward adjustments, and similarly, revenue estimates saw no upward revisions but three downward adjustments, indicating a decline in market confidence regarding the company's outlook.
See More
QuidelOrtho Releases Podcast on Syphilis Trends
- Syphilis Trend Analysis: QuidelOrtho's latest podcast discusses syphilis trends in the U.S., revealing that while primary and secondary syphilis cases have declined, congenital syphilis cases reached nearly 4,000 in 2024, highlighting a significant public health challenge.
- Screening Gaps: The podcast emphasizes that congenital syphilis is entirely preventable with timely diagnosis and treatment during pregnancy; however, current missed screening opportunities necessitate improvements in healthcare workflows to address this critical gap.
- CDC Data Insights: Andrea Ott-Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, interprets CDC data, indicating that despite a second consecutive year of decline in primary and secondary syphilis cases, the rising trend of congenital syphilis is alarming and requires urgent action.
- Actionable Recommendations: The podcast outlines actionable steps that health systems can take to enhance screening and treatment processes, thereby reducing the incidence of congenital syphilis and ensuring the health of mothers and newborns.
See More
